New Clinical Trial: Phase 2 Study of Nivolumab in classical Hodgkin Lymphoma Subjects after Failure of Autologous Stem Cell Transplant

The Weill Cornell Lymphoma Program has recently opened a new clinical trial for men and women with classical Hodgkin Lymphoma (cHL) subjects after failure of autologous stem cell transplant (ASCT). The study sponsor is Bristol-Myers Squibb, and the principal investigator at Weill Cornell is Dr. Lisa Roth. For more information about the study, please call Amelyn Rodgriguez, RN at (212) 746-1362 or e-mail Amelyn at amr2017@med.cornell.edu.

Key Eligibility

• Men and women age 18 and older
• Cohort A: Subjects not exposed to brentuximab vedotin
  – Documented absence of complete response (CR) after 90 days from stem cell infusion for most recent ASCT; or
  – Documented relapsed disease (after CR) or disease progression (after Partial Response (PR) or Stable Disease (SD))
• Cohort B: Subjects who failed treatment with brentuximab vedotin which was administered after failure of ASCT
  – Documented failure to achieve at least PR after the most recent treatment; or
  – Documented relapse disease (after CR) or disease progression (after PR or SD)
• Detailed eligibility reviewed when you contact the study team

Study Details

This clinical trial is for men and women with classical Hodgkin Lymphoma who failed autologous stem cell transplant (ASCT).  Subjects never treated with brentuximab vedotin are in Cohort A, or may have had prior brentuximab vedotin treatment as a salvage therapy after failure of ASCT are in Cohort B. The study is evaluating an experimental drug called nivolumab.

Nivolumab is in clinical development for the treatment of subjects with solid tumors and hematological (blood) malignancies. Nivolumab is an antibody (a type of human protein) that is being tested to see if it will allow the body’s immune system to work against tumor cells.

The purposes of this research study is to assess treatment with nivolumab with hopes that treatment with nivolumab will lead to clinical benefit, as demonstrated by a clinically meaningful objective response rate, including durable responses with substantial magnitude of tumor burden reduction in the heavily treated cHL subjects.

Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible. View all posts by lymphomaprogram